Assay design and sample collection can affect anti-John Cunningham virus antibody detection

Annals of Neurology

Volumn 69, Issue 2, 2011, Pages 429-430

  Goelz, Susan E ^a   Gorelik, Leonid ^a   Subramanyam, Meena ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JC VIRUS ANTIBODY; NATALIZUMAB; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANTIBODY DETECTION; ANTIGEN BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; JC VIRUS; LETTER; MULTIPLE SCLEROSIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SENSITIVITY AND SPECIFICITY;

ANTIBODIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; JC VIRUS; RESEARCH DESIGN; SPECIMEN HANDLING;

EID: 79952536982     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22304     Document Type: Letter

References (3)

1. Ryschkewitsch CF, Jensen PN, Monaco MC, et al. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab. Ann Neurol 2010; 68: 384-391.
2. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010; 68: 295-303.
3. Tyler KL,. Progressive multifocal leukoencephalopathy: can we reduce risk in patients receiving biological immunomodulatory therapies? Ann Neurol 2010; 68: 271-274.